SCHEMBL5327436

SCHEMBL5327436

O=S(=O)(c1ccc(Cl)cc1)N1CCN(c2cc(Cl)cc(Cl)c2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.65
ATM Q13315 1/20 0.63
L3MBTL1 Q9Y468 2/20 0.59
KMT2A Q03164 4/20 0.58
MAPT P10636 1/20 0.58
MEN1 O00255 3/20 0.58
HTT P42858 1/20 0.58
LSS P48449 1/20 0.58
PKM P14618 1/20 0.56
PKLR P30613 1/20 0.56
LMNA P02545 3/20 0.56
KDM4E B2RXH2 1/20 0.56
HSD17B10 Q99714 1/20 0.56
GAA P10253 1/20 0.55
THRB P10828 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
ALDH1A1 P00352 2/20 0.54
MAPK1 P28482 1/20 0.54
POLB P06746 1/20 0.54
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5250380 0.90 HSD11B1 (0.78) HSD11B1ATML3MBTL1KMT2AMAPT
SCHEMBL2839620 0.89 HSD11B1 (0.53) HSD11B1ATML3MBTL1KMT2AMEN1
SCHEMBL30005615 0.89 GCK (0.55) HSD11B1ATMKMT2AMAPTMEN1
SCHEMBL5256269 0.86 THRB (0.73) HSD11B1ATML3MBTL1KMT2AMAPT
SCHEMBL5249712 0.86 LMNA (0.68) HSD11B1ATML3MBTL1KMT2AMEN1
SCHEMBL4580893 0.86 ATM (0.81) ATML3MBTL1KMT2AMAPTMEN1
SCHEMBL10355428 0.86 ATM (0.81) ATML3MBTL1KMT2AMAPTMEN1
SCHEMBL2963235 0.85 ALDH1A1 (0.72) HSD11B1ATML3MBTL1KMT2AMAPT
SCHEMBL9312258 0.84 PKM (0.68) HSD11B1KMT2AMEN1HTTPKM
SCHEMBL5251036 0.83 MAPT (0.75) HSD11B1ATMKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758884-A2 N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
US-20060035884-A1 N-cyclic sulfonamido inhibitors of gamma secretase ELAN PHARMACEUTICALS, INC. (US) 2006-02-16 US claimed
WO-2005113542-A2 N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2005-12-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035884-A1 N-cyclic sulfonamido inhibitors of gamma secretase BACE1, BACE2, APH1B HSD11B1 1013/4885ATM 2550/4885L3MBTL1 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.